UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 10-Q
(Mark One)
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2012
OR
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
to
Commission File Number: 001-35112
Medgenics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
555 California Street, Suite 365, San Francisco, CA
|
94104
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(415) 568-2245
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name, former address and former
fiscal year, if changed since last report)
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes
x
No
¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). Yes
x
No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large
accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act (Check one):
Large accelerated filer
|
¨
|
Accelerated filer
|
¨
|
|
|
|
|
Non-accelerated filer
|
¨
(Do not check
if a smaller reporting company)
|
Smaller reporting company
|
x
|
Indicate by check mark whether the registrant
is a shell company (as defined in Exchange Act Rule 12b-2). Yes
¨
No
x
As of August 9, 2012, the registrant had
11,984,592 shares of common stock, $0.0001 par value, outstanding.
MEDGENICS, INC.
CONTENTS
|
|
Page
|
|
|
|
PART I
|
FINANCIAL INFORMATION
|
3
|
|
|
|
ITEM 1.
|
Financial Statements
|
3
|
|
|
|
ITEM 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
20
|
|
|
|
ITEM 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
28
|
|
|
|
ITEM 4.
|
Controls and Procedures
|
28
|
|
|
|
PART II
|
OTHER INFORMATION
|
29
|
|
|
|
ITEM 1.
|
Legal Proceedings
|
29
|
|
|
|
ITEM 1A.
|
Risk Factors
|
29
|
|
|
|
ITEM 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
29
|
|
|
|
ITEM 3.
|
Defaults Upon Senior Securities
|
30
|
|
|
|
ITEM 4.
|
Mine Safety Disclosures
|
30
|
|
|
|
ITEM 5.
|
Other Information
|
30
|
|
|
|
ITEM 6.
|
Exhibits
|
31
|
|
|
|
Signatures
|
|
32
|
PART I — FINANCIAL INFORMATION
ITEM 1 — Financial Statements
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
CONSOLIDATED BALANCE SHEETS
|
U.S. dollars in thousands
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2011
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
9,040
|
|
|
$
|
10,116
|
|
|
$
|
4,995
|
|
Accounts receivable and prepaid expenses
|
|
|
1,702
|
|
|
|
1,026
|
|
|
|
1,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
10,742
|
|
|
|
11,142
|
|
|
|
6,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LONG-TERM ASSETS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted lease deposits
|
|
|
57
|
|
|
|
49
|
|
|
|
52
|
|
Severance pay fund
|
|
|
264
|
|
|
|
353
|
|
|
|
259
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-term assets
|
|
|
321
|
|
|
|
402
|
|
|
|
311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROPERTY AND EQUIPMENT, NET
|
|
|
407
|
|
|
|
378
|
|
|
|
434
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
11,470
|
|
|
$
|
11,922
|
|
|
$
|
6,862
|
|
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
CONSOLIDATED BALANCE SHEETS
|
U.S. dollars in thousands
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2011
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade payables
|
|
$
|
917
|
|
|
$
|
869
|
|
|
$
|
903
|
|
Other accounts payable and accrued expenses
|
|
|
1,249
|
|
|
|
1,272
|
|
|
|
1,156
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
2,166
|
|
|
|
2,141
|
|
|
|
2,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LONG-TERM LIABILITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued severance pay
|
|
|
1,387
|
|
|
|
1,146
|
|
|
|
1,328
|
|
Liability in respect of warrants
|
|
|
4,107
|
|
|
|
1,321
|
|
|
|
478
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-term liabilities
|
|
|
5,494
|
|
|
|
2,467
|
|
|
|
1,806
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
7,660
|
|
|
|
4,608
|
|
|
|
3,865
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS' EQUITY:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock - $0.0001 par value; 100,000,000 shares authorized;
11,746,251, 9,638,948 and 9,722,725
shares issued and outstanding at June 30, 2012, June 30, 2011 and December 31, 2011, respectively
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
Additional paid-in capital
|
|
|
62,972
|
|
|
|
51,383
|
|
|
|
52,501
|
|
Deficit accumulated during the development stage
|
|
|
(59,163
|
)
|
|
|
(44,070
|
)
|
|
|
(49,505
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders' equity
|
|
|
3,810
|
|
|
|
7,314
|
|
|
|
2,997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity
|
|
$
|
11,470
|
|
|
$
|
11,922
|
|
|
$
|
6,862
|
|
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
CONSOLIDATED STATEMENTS OF OPERATIONS
|
U.S. dollars in thousands (except share and per share data)
|
|
|
Six months ended
June 30,
|
|
|
Three months ended
June 30,
|
|
|
Period from
January 27,
2000 (inception)
through
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
June 30, 2012
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
$
|
3,231
|
|
|
$
|
2,718
|
|
|
$
|
1,639
|
|
|
$
|
1,544
|
|
|
$
|
33,673
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less - Participation by the Office of the Chief Scientist
|
|
|
(1,486
|
)
|
|
|
(503
|
)
|
|
|
(464
|
)
|
|
|
(503
|
)
|
|
|
(6,779
|
)
|
U.S. Government grant
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(244
|
)
|
Participation by third party
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,067
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses, net
|
|
|
1,745
|
|
|
|
2,215
|
|
|
|
1,175
|
|
|
|
1,041
|
|
|
|
25,583
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
4,133
|
|
|
|
1,832
|
|
|
|
2,774
|
|
|
|
1,052
|
|
|
|
30,531
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excess amount of participation in research and development from third party
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,904
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(5,878
|
)
|
|
|
(4,047
|
)
|
|
|
(3,949
|
)
|
|
|
(2,093
|
)
|
|
|
(53,210
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial expenses
|
|
|
(3,773
|
)
|
|
|
(133
|
)
|
|
|
(2,972
|
)
|
|
|
(232
|
)
|
|
|
(7,053
|
)
|
Financial income
|
|
|
1
|
|
|
|
1,521
|
|
|
|
17
|
|
|
|
4
|
|
|
|
755
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before taxes on income
|
|
|
(9,650
|
)
|
|
|
(2,659
|
)
|
|
|
(6,904
|
)
|
|
|
(2,321
|
)
|
|
|
(59,508
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxes on income
|
|
|
8
|
|
|
|
2
|
|
|
|
8
|
|
|
|
2
|
|
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
|
|
$
|
(9,658
|
)
|
|
$
|
(2,661
|
)
|
|
$
|
(6,912
|
)
|
|
$
|
(2,323
|
)
|
|
$
|
(59,592
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share
|
|
$
|
(0.98
|
)
|
|
$
|
(0.37
|
)
|
|
$
|
(0.69
|
)
|
|
$
|
(0.26
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares of Common stock used in computing basic and diluted loss per share
|
|
|
9,893,072
|
|
|
|
7,212,074
|
|
|
|
10,032,760
|
|
|
|
9,033,672
|
|
|
|
|
|
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
|
U.S. dollars in thousands (except share and per share data)
|
|
|
Common stock
|
|
|
Additional
paid-in
capital
|
|
|
Deficit
accumulated
during the
development
stage
|
|
|
Total
stockholders'
equity
(deficit)
|
|
|
|
Shares
|
|
|
Amount
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2010
|
|
|
5,295,531
|
|
|
$
|
1
|
|
|
$
|
34,334
|
|
|
$
|
(41,409
|
)
|
|
$
|
(7,074
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Common stock at $4.54 per share and
warrants at $0.46 per share, net
|
|
|
2,624,100
|
|
|
|
(*)
|
|
|
|
10,389
|
|
|
|
|
|
|
|
10,389
|
|
Issuance of Common stock upon conversion of debentures
|
|
|
1,407,898
|
|
|
|
(*)
|
|
|
|
5,577
|
|
|
|
|
|
|
|
5,577
|
|
Exercise of warrants in January through June 2011
|
|
|
311,419
|
|
|
|
(*)
|
|
|
|
872
|
|
|
|
-
|
|
|
|
872
|
|
Stock based compensation related to options and warrants granted to consultants and employees
|
|
|
-
|
|
|
|
-
|
|
|
|
211
|
|
|
|
-
|
|
|
|
211
|
|
Loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,661
|
)
|
|
|
(2,661
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of June 30, 2011 (Unaudited)
|
|
|
9,638,948
|
|
|
$
|
1
|
|
|
$
|
51,383
|
|
|
$
|
(44,070
|
)
|
|
$
|
7,314
|
|
(*) Represents an amount lower than $1.
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
|
U.S. dollars in thousands (except share and per share data)
|
|
|
Common stock
|
|
|
Additional
paid-in
capital
|
|
|
Deficit
accumulated
during the
development
stage
|
|
|
Total
stockholders'
equity
|
|
|
|
Shares
|
|
|
Amount
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2011
|
|
|
9,722,725
|
|
|
$
|
1
|
|
|
$
|
52,501
|
|
|
$
|
(49,505
|
)
|
|
$
|
2,997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based compensation related to issuance of restricted common stock, January 2012
|
|
|
35,000
|
|
|
|
(*)
|
|
|
|
55
|
|
|
|
-
|
|
|
|
55
|
|
Issuance of Common stock to consultants at $4.84 and
$8.79 per share, March and June 2012
|
|
|
30,000
|
|
|
|
(*)
|
|
|
|
204
|
|
|
|
-
|
|
|
|
204
|
|
Issuance of Common stock and warrants at $4.90 per share,
net, June 2012
|
|
|
1,944,734
|
|
|
|
(*)
|
|
|
|
8,407
|
|
|
|
-
|
|
|
|
8,407
|
|
Exercise of options and warrants, January through June 2012
|
|
|
13,792
|
|
|
|
(*)
|
|
|
|
117
|
|
|
|
-
|
|
|
|
117
|
|
Stock based compensation related to options and
warrants granted to consultants and employees
|
|
|
-
|
|
|
|
-
|
|
|
|
1,688
|
|
|
|
-
|
|
|
|
1,688
|
|
Loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(9,658
|
)
|
|
|
(9,658
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of June 30, 2012 (Unaudited)
|
|
|
11,746,251
|
|
|
$
|
1
|
|
|
$
|
62,972
|
|
|
$
|
(59,163
|
)
|
|
$
|
3,810
|
|
(*) Represents an amount lower than $1.
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
U.S. dollars in thousands
|
|
|
|
Six months ended
June 30,
|
|
|
Period from
January 27,
2000
(inception)
through
June 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
|
|
$
|
(9,658
|
)
|
|
$
|
(2,661
|
)
|
|
$
|
(59,592
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to reconcile loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
72
|
|
|
|
36
|
|
|
|
1,153
|
|
Loss from disposal of property and equipment
|
|
|
-
|
|
|
|
-
|
|
|
|
330
|
|
Issuance of shares as consideration for providing security for letter of credit
|
|
|
-
|
|
|
|
-
|
|
|
|
16
|
|
Stock based compensation related to options, warrants and restricted shares granted to employees, directors and consultants
|
|
|
1,743
|
|
|
|
211
|
|
|
|
8,905
|
|
Interest and amortization of beneficial conversion feature of convertible note
|
|
|
|
|
|
|
-
|
|
|
|
759
|
|
Change in fair value of convertible debentures and warrants
|
|
|
3,717
|
|
|
|
(1,479
|
)
|
|
|
5,359
|
|
Accrued severance pay, net
|
|
|
54
|
|
|
|
24
|
|
|
|
1,123
|
|
Exchange differences on a restricted lease deposit
|
|
|
-
|
|
|
|
(1
|
)
|
|
|
3
|
|
Exchange differences on a long term loan
|
|
|
-
|
|
|
|
-
|
|
|
|
3
|
|
Increase in trade payables
|
|
|
219
|
|
|
|
126
|
|
|
|
1,726
|
|
Decrease (increase) in account receivable and prepaid expenses
|
|
|
(580
|
)
|
|
|
629
|
|
|
|
(1,702
|
)
|
Increase in other accounts payable and accrued expenses
|
|
|
93
|
|
|
|
118
|
|
|
|
1,796
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(4,340
|
)
|
|
|
(2,997
|
)
|
|
|
(40,121
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(45
|
)
|
|
|
(171
|
)
|
|
|
(2,064
|
)
|
Proceeds from disposal of property and equipment
|
|
|
-
|
|
|
|
-
|
|
|
|
173
|
|
Increase in restricted lease deposit
|
|
|
(5
|
)
|
|
|
(2
|
)
|
|
|
(60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
$
|
(50
|
)
|
|
$
|
(173
|
)
|
|
$
|
(1,951
|
)
|
The accompanying notes
are an integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
U.S. dollars in thousands
|
|
|
Six months ended
June 30,
|
|
|
Period from
January 27,
2000
(inception)
through
June 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of shares and warrants, net
|
|
$
|
8,407
|
|
|
$
|
10,389
|
|
|
$
|
42,908
|
|
Proceeds from exercise of options and warrants, net
|
|
|
28
|
|
|
|
38
|
|
|
|
1,039
|
|
Repayment of a long-term loan
|
|
|
-
|
|
|
|
-
|
|
|
|
(73
|
)
|
Proceeds from long term loan
|
|
|
-
|
|
|
|
-
|
|
|
|
70
|
|
Issuance of a convertible debenture and warrants
|
|
|
-
|
|
|
|
-
|
|
|
|
7,168
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
8,435
|
|
|
|
10,427
|
|
|
|
51,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents
|
|
|
4,045
|
|
|
|
7,257
|
|
|
|
9,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance of cash and cash equivalents at the beginning of the period
|
|
|
4,995
|
|
|
|
2,859
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance of cash and cash equivalents at the end of the period
|
|
$
|
9,040
|
|
|
$
|
10,116
|
|
|
$
|
9,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid during the period for:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
$
|
-
|
|
|
$
|
49
|
|
|
$
|
242
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxes
|
|
$
|
31
|
|
|
$
|
-
|
|
|
$
|
129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance expenses paid with shares
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Common stock upon conversion of a convertible debentures
|
|
$
|
-
|
|
|
$
|
5,577
|
|
|
$
|
8,430
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Common stock and warrants to consultants
|
|
$
|
205
|
|
|
$
|
-
|
|
|
$
|
1,356
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Classification of liability in respect of warrants into equity due to the exercise of warrants
|
|
$
|
88
|
|
|
$
|
834
|
|
|
$
|
1,219
|
|
The accompanying notes are an
integral part of the interim consolidated financial statements.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
U.S. dollars in thousands (except share and per share data)
|
a.
|
Medgenics, Inc. (the "Company") was incorporated in January 2000 in Delaware. The Company
has a wholly-owned subsidiary, Medgenics Medical Israel Ltd. (formerly Biogenics Ltd.) (the "Subsidiary"), which was
incorporated in Israel in March 2000. The Company and the Subsidiary are engaged in the research and development of products in
the field of biotechnology and associated medical equipment and are thus considered development stage companies as defined in Accounting
Standards Codification ("ASC") topic number 915,
"Development Stage Entities"
("ASC 915").
|
|
|
On December 4, 2007 the Company's Common stock was
admitted for trading on the AIM market of the London Stock Exchange.
|
|
|
On April 13, 2011 the Company completed an Initial Public Offering ("IPO") of its Common
stock on the NYSE MKT (formerly NYSE Amex), raising $10,389 in net proceeds.
|
|
b.
|
The Company and the Subsidiary are in the development stage. As reflected in the accompanying financial
statements, the Company incurred a loss for the six month period ended June 30, 2012 of $9,658 and had a negative cash flow from
operating activities of $4,340 during the six month period ended June 30, 2012. The accumulated deficit as of June 30, 2012 is
$59,163. The Company and the Subsidiary have not yet generated revenues from product sale. The Company previously generated income
from partnering on development programs and expects to continue to expand its partnering activity. Management’s plans also
include seeking additional investments and commercial agreements to continue the operations of the Company and the Subsidiary.
|
|
|
However, there is no assurance that the Company will be successful in its efforts to raise the
necessary capital and/or reach such commercial agreements to continue its planned research and development activities. The Company
believes that the net proceeds of the private placement (see note 3(b)2), plus Company's existing cash and cash equivalents, should
be sufficient to meet its operating and capital requirements into the first quarter of 2013. These conditions raise substantial
doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments
with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this
uncertainty.
|
|
c.
|
In April 2012, the Subsidiary received approval for an additional Research and Development program
from the Office of the Chief Scientist in Israel (“OCS”) for the period October 2011 through September 2012. The approval
allows for a grant of up to approximately $2,100 based on research and development expenses, not funded by others, of up to $3,900.
To date, $100 has been received.
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage
Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 2:-
|
SIGNIFICANT ACCOUNTING POLICIES
|
|
|
|
|
|
The accompanying unaudited interim
financial statements of Medgenics, Inc., a development stage company, have been prepared in accordance with accounting principles
generally accepted in the United States of America and the rules of the Securities and Exchange Commission ("SEC") and
should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K
for the year ended December 31, 2011 (2011 Form 10-K) as filed with the SEC. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations
for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate
the disclosure contained in the audited financial statements for the most recent fiscal year as reported in the 2011 Form 10-K,
have been omitted.
|
|
|
|
|
|
Impact
of recently issued accounting standards
|
|
a.
|
In May 2011, the FASB issued ASU 2011-04, "Fair Value Measurement (Topic 820): Amendments
to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs". The new guidance does not extend
the use of fair value accounting, but provides guidance on how it should be applied where its use is already required or permitted
by other standards within GAAP or International Financial Reporting Standards ("IFRS"). The new guidance also changes
the wording used to describe many requirements in GAAP for measuring fair value and for disclosing information about fair value
measurements and it clarifies the FASB's intent about the application of existing fair value measurements. The Company adopted
the provisions of this new guidance on January 1, 2012. The Company does not expect the adoption of the new provisions to have
a material impact on its consolidated financial position, results of operations or cash flows.
|
|
b.
|
On June 16, 2011, the Financial Accounting Standards Board issued ASU No. 2011-05,
"Presentation of Comprehensive Income". This standard eliminates the current option to report other comprehensive income
and its components in the statement of changes in shareholders’ equity and provides for either a single continuous statement
or two separate statements. Both options require companies to present the components of net income and total net income, the components
of other comprehensive income along with a total for other comprehensive income. Companies are also required to present reclassification
adjustments for items that are reclassified from other comprehensive income to net income within these statements. This standard
will be applied retrospectively for fiscal years beginning after December 15, 2011 with early adoption permitted. The disclosure
requirements of this standard will not have a material effect on the Company’s results of operations or financial position
as the amendment impacts presentation only.
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY
|
|
a.
|
In March 2012, the Company’s Board of Directors approved an amendment
to the stock incentive plan increasing the number of shares of Common stock authorized for issuance thereunder to a total of 2,478,571
shares of Common stock, subject to stockholder approval. The Company’s stockholders approved the amendment at the Company’s
annual meeting of stockholders on April 3, 2012.
|
|
b.
|
Issuance of shares, stock options and warrants to investors
|
|
1.
|
In January and February 2012, unexercised warrants held by several investors to purchase a total
of 34,804 shares of Common stock expired.
|
|
2.
|
In June 2012, the Company completed a private placement transaction in which the Company
issued 1,944,734 units with each unit consisting of one share of the Company’s Common stock and a warrant to purchase
0.75 of one share of Common stock. The warrants to purchase 1,458,550 of Common stock were issued with an exercise price of
$8.34 per share, will become exercisable on December 15, 2012 (which, if all were exercised in full, would result in the
issuance of 1,458,576 shares of Common stock due to the rounding of fractional shares) and will expire on June 18, 2017. In
addition, warrants to purchase 194,473 shares of Common stock having an exercise price of $9.17 per share were issued to the
placement agent, will become exercisable on December 18, 2012 and will expire on June 18, 2017. Each unit was sold for a
purchase price of $4.90 for total gross proceeds of $9,529 or approximately $8,407 in net proceeds after deducting private
placement fees of $953 and other offering costs of $169.
|
.
|
3.
|
In May and June 2012, three investors exercised warrants to purchase 46,711 shares of Common stock
at an exercise price of $5.37 per share using the cashless exercise method. Using this cashless exercise method, the investors
were issued 4,168 shares.
|
|
4.
|
Subsequent to the balance sheet date, in July 2012, 14 investors exercised warrants to
purchase 132,860 shares of Common stock at exercise prices ranging from $4.99 to $5.57 per share using the cashless exercise
method. Using this cashless exercise method, the investors were issued 84,110 shares. An additional three investors exercised
warrants to purchase 6,142 shares of Common stock at exercise prices ranging from $4.54 to $5.57 per share or an aggregate
exercise price of $29. In addition, in July and August 2012, 47,500 publicly traded warrants were exercised at an exercise price of $6.00 per share. The cash consideration received was $285.
|
|
c.
|
Issuance of shares, stock options and warrants to employees and
directors
|
|
1.
|
In
January 2012, the Company granted 15,000 options and 7,000 shares of restricted Common stock to each of 5 non-executive Directors
of the Company. These shares of Common stock are restricted in that they may not be disposed of and are not entitled to dividends.
50% of these shares were vested the day after the grant and 50% will vest one year from the grant date. All of the options are
for a term of 10 years, vest in three equal installments and have an exercise price of $2
.
66.
These options and restricted Common stock were granted under the stock incentive plan.
|
|
2.
|
In April 2012, the Company granted to the Company’s employees 47,254 options exercisable
at a price of $5.13 per share. The options have a 10 year term and vest in four equal annual tranches. The options were granted
under the stock incentive plan.
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY (CONT.)
|
|
c.
|
Issuance of shares, stock options and warrants to employees and
directors (cont.)
|
|
3.
|
In May 2012, unexercised options held by an employee to purchase 42,783 shares of Common stock
expired.
|
|
4.
|
In June 2012, the Chief Executive Officer of the Company transferred by gift 16,200 warrants with
an exercise price of $2.49 per share to four individuals who are not immediate family.
|
|
5.
|
In June 2012, a Director of the Company exercised options to purchase 4,286 shares of Common stock
at an exercise price of $6.55 per share or an aggregate exercise price of $28.
|
|
6.
|
In June 2012, an employee exercised options to purchase 6,723 shares of Common stock at an exercise
price of $5.47 per share using the cashless exercise method. The employee was issued 2,433 shares as a result of the option exercise.
|
|
7.
|
In June 2012, the Company granted the Chairman of the Board of the Company 900,000 options exercisable
at a price of $10.80 per share. The options have a 5 year term. 300,000 options vested immediately upon approval of the listing
application by the NYSE MKT and half of the remaining 600,000 options will vest on each of June 30, 2013 and June 30, 2014. The
total compensation of $3,975 will be recognized over the vesting period. The Company recorded an expense in the amount of $1,325
during the current period. These options were granted outside of the stock incentive plan.
|
|
8.
|
Subsequent to the balance sheet date, in July 2012, three employees exercised options to purchase
32,793 shares of Common stock at exercise prices ranging from $5.42 to $8.19 per share using the cashless exercise method. Using
this cashless exercise method, the employees were issued 16,857 shares.
|
|
9.
|
Subsequent to the balance sheet date, in July 2012, the Company granted to an employee 20,000 options
exercisable at a price of $14.50 per share. The options have a 10 year term and vest in four equal annual tranches. The options
were granted under the stock incentive plan.
|
|
10.
|
In December 2010, the Company granted the Executive Chairman of the Board of the Company 57,142
shares of restricted Common stock in compensation for his services in his new role as the Executive Chairman of the Board of the
Company. These shares of Common stock are restricted in that they may not be disposed of and are not entitled to dividends. These
restrictions will be removed in relation to 14,285 shares of Common stock on each of October 18, 2012 and October 18, 2013 and
the final 28,572 shares of Common stock on October 18, 2014. The value of these restricted shares of Common stock, $285, was based
on the fair value at the grant date and is being recognized as an expense using the straight line method. The Company recorded
expenses in the amount of $37 in the six months ended June 30, 2012.
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY (CONT.)
|
|
c.
|
Issuance of shares, stock options and warrants to employees and
directors (cont.)
|
A summary of the Company’s
activity for restricted shares granted to employees and directors is as follows:
|
|
Six months ended
June 30, 2012
|
|
Restricted shares
|
|
Outstanding
|
|
|
Exercisable
|
|
|
|
|
|
|
|
|
Number of restricted shares as of December 31, 2011
|
|
|
57,142
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
35,000
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
Number of restricted shares as of June 30, 2012
|
|
|
92,142
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
|
11.
|
A summary of the Company’s activity for options and warrants granted to employees and directors
is as follows:
|
|
|
Six months ended June 30, 2012
|
|
|
|
Number of
options and
warrants
|
|
|
Weighted
average
exercise
price
|
|
|
Weighted
average
remaining
contractual
terms
(years)
|
|
|
Aggregate
intrinsic value
price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2011
|
|
|
2,078,788
|
|
|
$
|
4.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
1,022,254
|
|
|
|
9.94
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(42,783
|
)
|
|
|
4.10
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(11,009
|
)
|
|
|
5.89
|
|
|
|
|
|
|
|
|
|
Given by the CEO to Investors
|
|
|
(16,200
|
)
|
|
|
2.49
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2012
|
|
|
3,031,050
|
|
|
$
|
6.12
|
|
|
|
4.90
|
|
|
$
|
14,171
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30, 2012
|
|
|
1,859,788
|
|
|
$
|
5.01
|
|
|
|
3.58
|
|
|
$
|
10,773
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest at June 30, 2012
|
|
|
2,972,487
|
|
|
$
|
6.09
|
|
|
|
4.85
|
|
|
$
|
14,001
|
|
As of June 30, 2012,
there was $713 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted to
employees. That cost is expected to be recognized over a weighted-average period of 2.8 years.
The aggregate intrinsic value
represents the total intrinsic value (the difference between the Company’s Common share fair value as of June 30, 2012 and
the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all
option holders exercised their options on June 30, 2012.
Calculation of aggregate intrinsic
value is based on the share price of the Company’s Common stock as of June 30, 2012 ($10.80 per share, as reported on the
NYSE MKT (formerly NYSE Amex)).
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY (CONT.)
|
|
d.
|
Issuance of shares, stock options and warrants to consultants
|
|
1.
|
In March 2012, the Company issued 15,000 shares of Common stock to a consultant. Total compensation,
measured as the grant date fair market value of the stock, amounted to $73 and was recorded as an operating expense in the statement
of operations.
|
|
2.
|
In April 2012, the Company granted options to purchase 15,280 shares of Common stock at an exercise
price of $5.13 per share to a consultant. The options have a 10 year term and vest in three equal annual tranches.
The options were granted under the stock incentive plan.
|
|
3.
|
In May 2012, two consultants exercised warrants to purchase 4,937 shares of Common stock at an
exercise price of $5.37 per share using the cashless exercise method. Using this cashless exercise method, the consultants were
issued 505 shares.
|
|
4.
|
In June 2012, the Company granted options to purchase 25,000 shares of Common stock at an exercise
price of $6.86 per share to each of two consultants. The options have a 10 year term and vest in three equal annual tranches. The
options were granted under the stock incentive plan. In addition, in June 2012, the Company issued 194,473 warrants to the placement
agent for its June 2012 private placement. See note 3(b)2.
|
|
5.
|
In June 2012, the Company issued 15,000 shares of Common stock to a consultant. Total compensation,
measured as the grant date fair market value of the stock, amounted to $131 and was recorded as an operating expense in the statement
of operations.
|
|
6.
|
In June 2012, a consultant exercised warrants to purchase 1,188 shares of Common stock at an exercise
price of $5.32 per share and 143 shares of Common stock at an exercise price of $5.19 per share using the cashless exercise method.
Using this cashless exercise method, the consultant was issued 363 shares. In addition, a consultant exercised warrants to purchase
4,675 shares of Common stock at an exercise price of $4.99 per share using the cashless exercise method. Using this cashless exercise
method, the consultant was issued 2,037 shares.
|
|
7.
|
Subsequent to the balance sheet date, in July 2012, the Company granted options to purchase 5,646
shares of Common stock at an exercise price of $14.50 per share to each of two consultants. The options have a 10 year term and
vest in three equal annual tranches. The options were granted under the stock incentive plan.
|
|
8.
|
Subsequent to the balance sheet date, in July and August 2012, seven consultants exercised
warrants to purchase 13,786 shares of Common stock at exercise prices ranging from $5.19 to $5.32 per share using the
cashless exercise method. Using this cashless exercise method, the consultants were issued 8,523 shares. In addition, in
August 2012, a consultant exercised warrants to purchase 75,000 shares of Common stock at an exercise price of $4.80 per
share or an aggregate exercise price of $360.
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY (CONT.)
|
|
d.
|
Issuance of shares, stock options and warrants to consultants (cont.)
|
|
9.
|
A summary of the Company's activity for warrants and options granted to consultants under the stock
incentive plan is as follows:
|
|
|
Six months ended June 30, 2012
|
|
|
|
Number of
options and
warrants
|
|
|
Weighted
average
exercise
price
|
|
|
Weighted
average
remaining
contractual
terms
(years)
|
|
|
Aggregate
intrinsic value
price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2011
|
|
|
540,338
|
|
|
$
|
5.49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
259,753
|
|
|
|
8.49
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(10,943
|
)
|
|
|
5.20
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2012
|
|
|
789,148
|
|
|
$
|
6.47
|
|
|
|
4.23
|
|
|
$
|
3,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30, 2012
|
|
|
472,096
|
|
|
$
|
5.30
|
|
|
|
2.72
|
|
|
$
|
2,598
|
|
As of June 30, 2012, there
was $51 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted to consultants
under the Company's stock
incentive plan. That cost is expected to be recognized over a weighted-average period of 1.4 years.
Calculation of aggregate intrinsic
value is based on the share price of the Company’s Common stock as of June 30, 2012 ($10.80 per share, as reported on the
NYSE MKT (formerly NYSE Amex)).
Compensation expense related to
shares, warrants and options granted to employees, directors and consultants was recorded in the Statement of Operations in the
following line items:
|
|
Six months ended
June 30,
|
|
|
Three months ended
June 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
$
|
98
|
|
|
$
|
55
|
|
|
$
|
72
|
|
|
$
|
25
|
|
General and administrative expenses
|
|
|
1,849
|
|
|
|
156
|
|
|
|
1,626
|
|
|
|
98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,947
|
|
|
$
|
211
|
|
|
$
|
1,698
|
|
|
$
|
123
|
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’
EQUITY (CONT.)
|
|
f.
|
Summary of options and warrants:
|
A summary of all the options
and warrants outstanding as of June 30, 2012 is presented in the following table:
|
|
As of June 30, 2012
|
|
Options / Warrants
|
|
Exercise
Price per
Share ($)
|
|
|
Options and
Warrants
Outstanding
|
|
|
Options and
Warrants
Exercisable
|
|
|
Weighted
Average
Remaining
Contractual
Terms (in years)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted to Employees and Directors
|
|
|
2.49
|
|
|
|
182,806
|
|
|
|
182,806
|
|
|
|
3.8
|
|
|
|
|
2.66
|
|
|
|
75,000
|
|
|
|
-
|
|
|
|
9.5
|
|
|
|
|
3.14
|
|
|
|
244,857
|
|
|
|
35,000
|
|
|
|
9.4
|
|
|
|
|
3.64
|
|
|
|
40,000
|
|
|
|
-
|
|
|
|
9.0
|
|
|
|
|
3.86
|
|
|
|
11,429
|
|
|
|
-
|
|
|
|
9.2
|
|
|
|
|
5.13
|
|
|
|
47,254
|
|
|
|
-
|
|
|
|
9.8
|
|
|
|
|
5.47
|
|
|
|
42,813
|
|
|
|
42,813
|
|
|
|
1.0
|
|
|
|
|
6.55
|
|
|
|
47,142
|
|
|
|
12,857
|
|
|
|
8.5
|
|
|
|
|
7.35
|
|
|
|
332,046
|
|
|
|
332,046
|
|
|
|
0.4
|
|
|
|
|
8.19
|
|
|
|
218,713
|
|
|
|
65,275
|
|
|
|
8.2
|
|
|
|
|
10.80
|
|
|
|
900,000
|
|
|
|
300,000
|
|
|
|
5.0
|
|
|
|
|
|
|
|
|
2,142,060
|
|
|
|
970,797
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted to Consultants
|
|
|
4.20
|
|
|
|
19,354
|
|
|
|
12,903
|
|
|
|
2.4
|
|
|
|
|
5.13
|
|
|
|
15,280
|
|
|
|
-
|
|
|
|
9.8
|
|
|
|
|
5.47
|
|
|
|
19,354
|
|
|
|
19,354
|
|
|
|
1.3
|
|
|
|
|
6.65
|
|
|
|
38,136
|
|
|
|
12,712
|
|
|
|
8.4
|
|
|
|
|
6.86
|
|
|
|
50,000
|
|
|
|
-
|
|
|
|
10.0
|
|
|
|
|
7.35
|
|
|
|
46,045
|
|
|
|
46,045
|
|
|
|
0.4
|
|
|
|
|
8.19
|
|
|
|
38,136
|
|
|
|
12,712
|
|
|
|
8.2
|
|
|
|
|
|
|
|
|
262,305
|
|
|
|
103,726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Options
|
|
|
|
|
|
|
2,368,365
|
|
|
|
1,074,523
|
|
|
|
|
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 3:-
|
STOCKHOLDERS’ EQUITY (CONT.)
|
|
f.
|
Summary of options and warrants (cont.):
|
|
|
As of June 30, 2012
|
|
Options / Warrants
|
|
Exercise
Price per
Share ($)
|
|
|
Options and
Warrants
Outstanding
|
|
|
Options and
Warrants
Exercisable
|
|
|
Weighted
Average
Remaining
Contractual
Terms (in years)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted to Employees and Directors
|
|
|
2.49
|
|
|
|
888,990
|
|
|
|
888,990
|
|
|
|
3.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted to Consultants
|
|
|
3.19
|
|
|
|
11,370
|
|
|
|
11,370
|
|
|
|
3.2
|
|
|
|
|
4.01
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
4.0
|
|
|
|
|
4.80
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
4.1
|
|
|
|
|
4.99
|
|
|
|
6,635
|
|
|
|
6,635
|
|
|
|
3.8
|
|
|
|
|
5.19
|
|
|
|
16,579
|
|
|
|
16,579
|
|
|
|
0.4
|
|
|
|
|
5.32
|
|
|
|
31,637
|
|
|
|
31,637
|
|
|
|
0.2
|
|
|
|
|
5.57
|
|
|
|
102,149
|
|
|
|
102,149
|
|
|
|
1.1
|
|
|
|
|
9.17
|
|
|
|
194,473
|
|
|
|
-
|
|
|
|
4.9
|
|
|
|
|
|
|
|
|
562,843
|
|
|
|
368,370
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted to Investors
|
|
|
0.0002
|
|
|
|
35,922
|
|
|
|
35,922
|
|
|
|
3.8
|
|
|
|
|
2.49
|
|
|
|
16,200
|
|
|
|
16,200
|
|
|
|
3.8
|
|
|
|
|
4.58
|
|
|
|
428,571
|
|
|
|
428,571
|
|
|
|
3.2
|
|
|
|
|
4.99
|
|
|
|
73,383
|
|
|
|
73,383
|
|
|
|
3.8
|
|
|
|
|
5.32
|
|
|
|
119,421
|
|
|
|
119,421
|
|
|
|
0.3
|
|
|
|
|
5.57
|
|
|
|
50,721
|
|
|
|
50,721
|
|
|
|
0.4
|
|
|
|
|
6.00
|
|
|
|
2,829,000
|
|
|
|
2,829,000
|
|
|
|
3.8
|
|
|
|
|
8.34
|
|
|
|
1,458,550
|
|
|
|
-
|
|
|
|
4.9
|
|
|
|
|
|
|
|
|
5,011,768
|
|
|
|
3,553,218
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
|
|
|
|
6,463,601
|
|
|
|
4,810,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Options and Warrants
|
|
|
|
|
|
|
8,831,966
|
|
|
|
5,885,101
|
|
|
|
|
|
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
|
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 4:-
|
FAIR VALUE MEASURMENTS
|
The Company
adopted the provision of ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820") on January 1, 2008.
ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities
required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact
and consider assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer
restrictions and risk of nonperformance.
ASC 820 also
establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest
level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to
measure fair value:
Level 1 - quoted
prices in active markets for identical assets or liabilities;
Level 2 - inputs
other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar
assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs
that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
or
Level 3
- unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities.
The Company
classified certain warrants issued to investors through the years 2006 and 2007 and warrants issued to the purchasers of the 2010
Convertible Debentures as a liability and measure them at fair value according to ASC 815-40-15-7I.
The changes
in level 3 liabilities measured at fair value on a recurring basis:
|
|
Fair value
of liability in respect
of warrants
|
|
|
|
|
|
Balance as of December 31, 2010
|
|
$
|
3,670
|
|
|
|
|
|
|
Change in fair value of the liability in respect of warrants
|
|
|
(3,192
|
)
|
|
|
|
|
|
Balance as of December 31, 2011
|
|
|
478
|
|
|
|
|
|
|
Change in fair value of the liability in respect of warrants
|
|
|
3,629
|
|
|
|
|
|
|
Balance as of June 30, 2012 (unaudited)
|
|
$
|
4,107
|
|
* * * * * * * * * * * * * *
ITEM 2 — Management’s Discussion and Analysis
of Financial Condition and Results of Operations
The following discussion and analysis
of our financial condition and results of operations should be read together with our financial statements and related notes appearing
elsewhere in this Quarterly Report on Form 10-Q.
Forward Looking Statements
This quarterly report on Form 10-Q contains
“forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize
or prove incorrect could cause our results to differ materially from those expressed or implied by such forward-looking statements.
The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by
the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “will,”
“plan,” “project,” “seek,” “should,” “target,” “will,”
“would” and similar expressions or variations intended to identify forward-looking statements. These statements are
based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking
statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain
events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause
or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors”
in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011, and any updates to those risk factors
included in Part II, Item 1A of this Quarterly Report on Form 10-Q. Furthermore, such forward-looking statements speak only as
of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect
events or circumstances after the date of such statements.
Overview
We are an autologous protein-therapeutics
medical technology company, developing our Biopump Platform Technology to provide sustained protein therapy to potentially treat
a range of chronic diseases and conditions.
Since our inception on January 27, 2000,
we have focused our efforts on research and development and clinical trials and have received no revenue from product sales. We
have funded our operations principally through equity and debt financings, participation from the Office of the Chief Scientist
(“OCS”) in Israel and a collaborative agreement. Our operations to date have been primarily limited to organizing
and staffing our company, developing the Biopump Platform Technology and its applications, developing and initiating clinical trials
for our product candidates, and improving and maintaining our patent portfolio.
We have generated significant losses to
date, and we expect to continue to generate losses as we progress towards the commercialization of our product candidates. We
have incurred net losses of approximately $9.7 million and $59.6 million for six month period ended June 30, 2012 and for the period
from inception through June 30, 2012, respectively. As of June 30, 2012, we had stockholders’ equity of approximately $3.8
million. We are unable to predict the extent of any future losses or when we will become profitable, if at all.
Although we have not yet generated revenues
from product sales, we have generated income from partnering on development programs and we expect to expand our partnering activity.
In 2009, we signed a preclinical development
and option agreement with Baxter Healthcare, a market leader in the field of hemophilia, representing our first collaboration agreement
for the Biopump Platform Technology. The agreement was extended in 2010 and 2011. Pursuant to this agreement, the healthcare
company provided funding for preclinical development of our Biopump Platform Technology to produce and deliver the clotting protein
Factor VIII for the sustained treatment of hemophilia. Under the terms of the collaboration agreement, we received $3.97
million. The agreement, as extended, expired on September 30, 2011.
On June 18, 2012, we completed a private
placement transaction in which we issued an aggregate of 1,944,734 units with each unit consisting of one share of our common stock
and a warrant to purchase 0.75 shares of our common stock. The warrants to purchase an aggregate of 1,458,550 shares of common
stock were issued with an exercise price of $8.34 per share, will become exercisable on December 15, 2012 (which, if all were exercised
in full, would result in the issuance of 1,458,576 shares of common stock due to the rounding of fractional shares) and will expire
on June 18, 2017. In addition, warrants to purchase 194,473 shares of our common stock having an exercise price of $9.17 per share
were issued to the placement agent, will become exercisable on December 18, 2012 and will expire on June 18, 2017. Each unit was
sold for a purchase price of $4.90 for total gross proceeds of approximately $9.53 million, or approximately $8.41 million in net
proceeds after deducting private placement fees of $0.95 million and other offering costs of $0.17 million.
United States Initial Public Offering (“IPO”):
On April 13, 2011, we completed the IPO
of our common stock and redeemable common stock purchase warrants, both listed on the NYSE Amex. We issued 2,624,100 shares of
common stock, including 164,100 shares pursuant to the exercise of the underwriters’ over-allotment option, at a price of
$4.54 per share and redeemable common stock purchase warrants to purchase 2,829,000 shares including 369,000 warrants pursuant
to the exercise of the underwriters’ over-allotment option, at a price of $0.46 per warrant for total gross proceeds of $13.21 million,
or approximately $10.39 million in net proceeds after deducting underwriting discounts and commissions of $1.45 million and other
offering costs of approximately $1.37 million.
On the closing date of the IPO (April 13,
2011), $0.57 million of convertible debentures issued in 2009 (the “2009 Debentures”) were automatically converted
at a conversion price of $2.724 per share of common stock into an aggregate 209,656 shares of common stock and we issued 5-year
warrants to purchase 84,693 shares of common stock at an initial exercise price of $4.99 per share in connection with the conversion
of the 2009 Debentures. On the same date, $4.00 million of convertible debentures issued in 2010 (the “2010 Debentures”)
were automatically converted at a conversion price of $3.405 per share of common stock into an aggregate 1,198,242 shares of common
stock. An additional 2,534 share of common stock were issued to the holders of the 2010 Debentures in November 2011 to compensate
the 2010 Debenture holders for a minor portion of the interest which had been accrued but not paid at the time of conversion.
In connection with our IPO, the exercise
price of certain warrants and options which were initially issued with round-down protection mechanism were adjusted based upon
the share value as determined in the IPO.
Financial Operations Overview
Research and Development Expense
Research and development expense consists
of: (i) internal costs associated with our development activities; (ii) payments we make to third party contract research organizations,
contract manufacturers, clinical trial sites, and consultants; (iii) technology and intellectual property license costs; (iv) manufacturing
development costs; (v) personnel related expenses, including salaries, benefits, travel, and related costs for the personnel involved
in product development; (vi) activities related to regulatory filings and the advancement of our product candidates through preclinical
studies and clinical trials; and (vii) facilities and other allocated expenses, which include direct and allocated expenses for
rent, facility maintenance, as well as laboratory and other supplies. All research and development costs are expensed as incurred.
Conducting a significant amount of development
is central to our business model. Through June 30, 2012, we incurred approximately $33.7 million in gross research and development
expenses since our inception on January 27, 2000. Product candidates in later-stage clinical development generally have higher
development costs than those in earlier stages of development, primarily due to the significantly increased size and duration of
the clinical trials. We plan to increase our research and development expenses for the foreseeable future in order to complete
development of our two most advanced product candidates, the EPODURE Biopump and the INFRADURE Biopump, and our earlier-stage research
and development projects including our HEMODURE Biopump producing Factor VIII.
The process of conducting pre-clinical studies
and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product
candidate and clinical trial may be affected by a variety of factors, including, among others, the quality of the product candidate’s
early clinical data, investment in the program, competition, manufacturing capabilities and commercial viability. As a result of
these uncertainties, together with the uncertainty associated with clinical trial enrollments and the risks inherent in the development
process, we are unable to determine the duration and completion costs of current or future clinical stages of our product candidates
or when, or to what extent, we will generate revenues from the commercialization and sale of any of our product candidates. Development
timelines, probability of success and development costs vary widely. We are currently focused on developing our two most advanced
product candidates, the EPODURE Biopump and the INFRADURE Biopump, as well as our HEMODURE Biopump producing Factor VIII and associated
devices for implementing the platform technology.
Research and development expenses are shown
net of participation by third parties. The excess of the recognized amount received from the healthcare company over the amount
of research and development expenses incurred during the period for the collaboration agreement is recognized as other income within
operating income.
General and Administrative Expense
General and administrative expense consists
primarily of salaries and other related costs, including stock-based compensation expense, for persons serving in our executive,
finance and accounting functions. Other general and administrative expense includes facility-related costs not otherwise included
in research and development expense, costs associated with conferences and industry shows, and professional fees for legal services
and accounting services. We expect that our general and administrative expenses will increase as we add personnel and increase
our activities. Since our inception on January 27, 2000 through June 30, 2012, we have recorded approximately $30.5 million in
general and administrative expense.
Other Income
We have not generated any product revenue
since our inception, but, in connection with our first collaboration agreement, we received $3.97 million from Baxter Healthcare
during 2009 through 2011 of which $2.9 million was recognized as other income. To date, we have funded our operations primarily
through equity and debt financings and funding from the Israeli OCS. If our product development efforts result in clinical success,
regulatory approval and successful commercialization of any of our products, we would expect to generate revenue from sales or
licenses of any such products.
Financial Income and Expense
Financial expense consists primarily of
interest and amortization of beneficial conversion feature of convertible note, convertible debentures valuations and interest
incurred on debentures.
Interest income consists primarily of warrant
valuations and interest earned on our cash and cash equivalents and marketable securities.
Results of Operations for the Six Months Ended June 30, 2012
and 2011
Research and Development Expenses, net
Gross research and development expenses
for the six months ended June 30, 2012 were $3.23 million, increasing from $2.72 million for the same period in 2011 due to an
increase in the use of materials and sub-contractors in connection with preparations for our planned phase II EPODURE clinical
trials in Israel and the United States, and preparations for the trials of INFRADURE in Israel, as well as an increase in research
and development personnel.
Research and development expenses, net for
the six months ended June 30, 2012 were $1.75 million, decreasing from $2.22 million for the same period in 2011. The decrease
in the research and development expenses, net was due to the participation by the OCS of $1.49 million in the six months ended
June 30, 2012 compared with $0.50 million for the same period in 2011, which was partially offset by the increase in the gross
research and development expenses as detailed above
.
General and Administrative Expenses
General and administrative expenses for
the six months ended June 30, 2012 were $4.13 million, increasing from $1.83 million for the same period in 2011 primarily due
to increased legal fees and professional services, increased activities in the United States and stock-based compensation expenses
related to equity granted to consultants and to the newly appointed Chairman of the Board.
Financial Income and Expenses
Financial expenses for the six months ended
June 30, 2012 were $3.77 million, increasing from $0.13 million for the same period in 2011. This increase of $3.64 million was
mainly due to the change in valuation of the warrant liability.
Financial income for the six months ended
June 30, 2012 was de minimis, decreasing from $1.52 million for the same period in 2011. The decrease of approximately $1.52 million
was primarily due to the change in valuation of the warrant liability.
Results of Operations for the Three Months Ended June 30,
2012 and 2011
Research and Development Expenses, net
Gross research and development expenses
for the three months ended June 30, 2012 were $1.64 million, increasing from $1.54 million for the same period in 2011 due to an
increase in the use of materials and sub-contractors in connection with preparations for our planned phase II EPODURE clinical
trials in Israel and the United States, and preparations for the trials of INFRADURE in Israel, as well as an increase in research
and development personnel.
Research and development expenses, net for
the three months ended June 30, 2012 were $1.18 million, increasing from $1.04 million for the same period in 2011. The increase
in the research and development expenses, net was mainly due to the increase in the gross research and development expenses as
detailed above
.
General and Administrative Expenses
General and administrative expenses for
the three months ended June 30, 2012 were $2.77 million, increasing from $1.05 million for the same period in 2011 primarily due
to increased legal fees and professional services, increased activities in the United States and stock-based compensation expenses
related to equity granted to consultants and to the newly appointed Chairman of the Board.
Financial Income and Expenses
Financial expenses for the three months
ended June 30, 2012 were $2.97 million, increasing from $0.23 million for the same period in 2011. This increase was mainly due
to the change in valuation of the warrant liability.
Financial income for the three months ended
June 30, 2012 was $0.02 million, increasing from a de minimis amount for the same period in 2011. Financial income is mainly due
to the change in foreign currency exchange rates.
Liquidity and Capital Resources
Sources of Liquidity
We have financed our operations primarily
through a combination of equity issues, debt issues and grants from the OCS and other third parties.
We recorded $6.78 million from inception
through June 30, 2012 in development grants from the OCS, of which $1.49 million was recorded during the six months ended June
30, 2012.
On April 13, 2011, we completed our IPO
in the United States of our common stock and redeemable common stock purchase warrants which are both listed on the NYSE Amex.
We issued 2,624,100 shares of common stock, including 164,100 shares pursuant to the exercise of the underwriters’ over-allotment
option, at a price of $4.54 per share and redeemable common stock purchase warrants to purchase 2,829,000 shares, including 369,000
warrants pursuant to the exercise of the underwriters’ over-allotment option, at a price of $0.46 per warrant for total gross
proceeds of $13.21 million or approximately $10.39 million in net proceeds after deducting underwriting discounts and commissions
of $1.45 million and other offering costs of approximately $1.37 million.
On the closing date of the IPO (April 13,
2011), $0.57 million of 2009 Debentures were automatically converted at a conversion price of $2.724 per share of common stock
into an aggregate amount of 209,656 shares and we issued 5-year warrants to purchase 84,693 shares at an initial exercise price
of $4.99 per share in connection with the conversion of the 2009 Debentures. On the same date, $4.00 million of 2010 Debentures
were automatically converted at a conversion price of $3.405 per share into an aggregate amount of 1,198,242 shares. An additional
2,534 shares of common stock were issued to holders of the 2010 Debentures in November 2011 to compensate the 2010 Debenture holders
for a minor portion of the interest which had been accrued but not paid at the time of conversion.
On June 18, 2012, we completed a private
placement transaction in which we issued an aggregate of 1,944,734 units with each unit consisting of one share of our common stock
and a warrant to purchase 0.75 shares of our common stock. The warrants to purchase an aggregate of 1,458,550 shares of common
stock were issued with an exercise price of $8.34 per share, will become exercisable on December 15, 2012 (which, if all were exercised
in full, would result in the issuance of 1,458,576 shares of common stock due to the rounding of fractional shares) and will expire
on June 18, 2017. In addition, warrants to purchase 194,473 shares of our common stock having an exercise price of $9.17 per share
were issued to the placement agent, will become exercisable on December 18, 2012 and will expire on June 18, 2017. Each unit was
sold for a purchase price of $4.90 for total gross proceeds of approximately $9.53 million, or approximately $8.41 million in net
proceeds after deducting private placement fees of $0.95 million and other offering costs of $0.17 million.
Cash Flows
We had cash and cash equivalents of $9.04
million at June 30, 2012 and $5.0 million at December 31, 2011. The increase in our cash balance during the six months ended June
30, 2012 was primarily the result of the private placement transaction completed in June 2012.
Net cash used in operating activities of
$4.34 million for the six months ended June 30, 2012 and $3.00 million for the six months ended June 30, 2011 primarily reflected
our cash expenses for our operations. The increase in the net cash used in operating activities is due to an increase in operating
activity.
Net cash used in investing activities of
$0.05 million for the six months ended June 30, 2012 and $0.17 million for the six months ended June 30, 2011 relates mainly to
our purchases of property and equipment.
Net cash provided by financing activities
was $8.44 million and $10.43 million for the six months ended June 30, 2012 and June 30, 2011, respectively. Our cash flows from
financing activities during the six months ended June 30, 2012 were primarily proceeds from the private placement transaction in
June 2012 while our cash flows from financing activities during the six months ended June 30, 2011 were primarily proceeds from
the IPO.
Funding Requirements
We expect to raise additional funds through
the sale of our securities and through entering into licensing or other commercialization agreements for all or parts of applications
of our Biopump Platform Technology to fund our continuing operations. If we are unable to enter into such agreements on terms acceptable
to us, we will continue to incur losses from operations for the foreseeable future. We expect to incur increasing research and
development expenses, including expenses related to the hiring of personnel and additional clinical trials, as we further develop
the EPODURE Biopump, the INFRADURE Biopump and the HEMODURE Biopump. We expect that our general and administrative expenses will
also increase as we expand our finance and administrative staff, add infrastructure, and incur additional costs related to being
a public company in the United States, including investor relations programs, and increased professional fees. Our future capital
requirements will depend on a number of factors, including the timing and outcome of clinical trials and regulatory approvals,
the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual
property rights, the acquisition of licenses to new products or compounds, the status of competitive products, the availability
of financing, and our success in developing markets for our product candidates.
Without taking into account any revenue
we may receive as a result of licensing or other commercialization agreements we are pursuing, we believe that the net proceeds
we received from our private placement transaction completed in June 2012, plus our existing cash and cash equivalents, will be
sufficient to enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2013. We
have based this estimate on assumptions that may prove to be wrong and we could use our available resources sooner than we currently
expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates,
we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated
clinical trials.
We do not anticipate that we will generate
revenue from the sale of products for at least five years; however, we do intend to seek licensing or other commercialization agreements
similar to our agreement relating to the development of our HEMODURE Biopump producing Factor VIII. We anticipate that the funds
received as a result of such agreements may be sufficient to fund our operations in the future. In the absence of additional equity
or debt funding or adequate funding from commercialization agreements, we expect our continuing operating losses to result in increases
in our cash used in operations over the next several quarters and years.
Absent significant corporate collaboration
and licensing arrangements, we will need to finance our future cash needs through public or private equity offerings, or debt financings
in the near term. We do not currently have any commitments for future external funding. If the trading price of our common stock
remains above $6.00 per share, we anticipate receiving cash exercise proceeds upon the exercise of our outstanding warrants, primarily
the warrants issued in the IPO which have a current exercise price of $6.00 per share (the “IPO Warrants”), over the
next three and a half years. To date, we have received gross proceeds of approximately $0.28 million upon the exercise of the IPO
warrants. We may also seek to sell additional equity or debt securities or obtain a bank credit facility. The sale of additional
equity or debt securities, if convertible, could result in dilution to our stockholders. The incurrence of indebtedness would result
in increased fixed obligations and could also result in covenants that would restrict our operations.
These conditions raise doubt about our ability
to continue as a going concern. Our plans include seeking additional investments and commercial agreements to continue our operations.
However, there is no assurance that we will be successful in our efforts to raise the necessary capital and/or reach such commercial
agreements to continue our planned research and development activities.
Critical Accounting Policies
Our management’s discussion and analysis
of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate
these estimates and judgments, including those described below. We base our estimates on our historical experience and on various
other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
and experiences may differ materially from these estimates.
While our significant accounting policies
are more fully described in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe
that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial
results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.
Convertible Debentures
We irrevocably elected to initially and
subsequently measure the convertible debentures issued in 2009 and 2010 entirely at fair value, in accordance with Accounting Standards
Codification No. 825-10. As a result, we did not separate the embedded derivative instrument from the host contract and account
for it as a derivative instrument. The convertible debentures were subject to remeasurement at each balance sheet date, and any
change in fair value was recognized as a component of financial income (expense), net in the statements of operations. We estimated
the fair value of these convertible debentures at the respective balance sheet dates using the Binomial option pricing model. We
used a number of assumptions to estimate the fair value, including the remaining contractual terms of the convertible debentures,
risk-free interest rates, expected dividend yield and expected volatility of the price of the underlying common stock.
During the six months ended June 30, 2011,
we recorded financial income of $0.04 million to reflect the decrease in the fair value of the convertible debentures. We did not
record comparable income during the six months ended June 30, 2012 because all of the convertible debentures were converted to
common stock on the closing date of the IPO (April 13, 2011).
Liability in Respect of Warrants
In 2010 we issued warrants with an exercise
price that is subject to downward adjustment. In addition, in 2006 and 2007, we issued warrants that included price protection
in the event of sales of securities below the then current exercise price. In accordance with Accounting Standards Codification
No. 815-40-15-7I, we classified these warrants as a liability at their fair value. The warrants liability will be remeasured at
each reporting period until exercised or expired. The increase in the fair value of the warrants during the six months ended June
30, 2012 of $3.72 million and the decrease in the fair value of the warrants during the six months ended June 30, 2011 of $1.52
million are reported in the Statements of Operations as financial expense or income, respectively.
We estimate the fair value of these warrants
at the respective balance sheet dates using the Binomial option pricing model. We use a number of assumptions to estimate the fair
value, including the remaining contractual terms of the warrants, risk-free interest rates, expected dividend yield and expected
volatility of the price of the underlying common stock. These assumptions could differ significantly in the future, thus resulting
in variability of the fair value which would impact the results of operations in the future.
Stock-Based Compensation
We account for stock options according to
the Accounting Standards Codification No. 718 (ASC 718) “Compensation – Stock Compensation.” Under ASC 718, stock-based
compensation cost is measured at grant date, based on the estimated fair value of the award, and is recognized as an expense over
the employee’s requisite service period on a straight-line basis.
We account for stock options granted to
non-employees on a fair value basis using an option pricing method in accordance with ASC 718. The initial non-cash charge to operations
for non-employee options with vesting are revalued at the end of each reporting period based upon the change in the fair value
of the options and amortized to consulting expense over the related vesting period.
For the purpose of valuing options and warrants
during the six months ended June 30, 2012 and 2011, we used the Binomial options pricing model. To determine the risk-free interest
rate, we utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of
our awards. We estimated the expected life of the options granted based on anticipated exercises in the future periods assuming
the success of our business model as currently forecast. The expected dividend yield reflects our current and expected future policy
for dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining historical
volatilities for publicly traded industry peers as we do not have sufficient trading history for our common stock. We will continue
to analyze the expected stock price volatility and expected term assumptions as more historical data for our common stock becomes
available. Given the senior nature of the roles of our employees, directors and officers, we currently estimate that we will experience
no forfeitures for those options currently outstanding.
Off-Balance Sheet Arrangements
Pursuant to our license agreement with Yissum
Research Development Company of the Hebrew University (Yissum), Yissum
granted
us a license
of certain patents for commercial development, production, sublicense and marketing of products to be based on its know-how and
research results. In consideration, we agreed to pay Yissum the following amounts, provided, however, that the total aggregate
payment of royalties and sublicense fees by us to Yissum shall not exceed $10 million:
|
·
|
non-refundable license fee of $0.4 million to be paid in three installments, as follows:
|
|
·
|
$0.05 million when the accrued investments in us by any third party after May 23, 2005 equal at least $3 million (paid in 2007);
|
|
·
|
$0.15 million when the accrued investments in us by any third party after May 23, 2005 equal at least $12 million (paid in
second quarter of 2010); and
|
|
·
|
$0.2 million when the accrued investments in us by any third party after May 23, 2005 equal at least $18 million (paid
in April 2011);
|
|
·
|
royalties at a rate of 5% of net sales of product incorporating the licensed technology; and
|
|
·
|
sublicense fees at a rate of 9% of sublicense considerations received by us.
|
The Yissum license will expire upon the
later of the twentieth anniversary of our first commercial sale of products utilizing the licensed technology and the expiration
of the last Yissum patent licensed to us, which is expected to be approximately July 2022.
In 2007, we signed an agreement with Baylor
College of Medicine (BCM) whereby BCM granted us a non-exclusive worldwide license to use, market, sell, lease and import certain
technology (BCM technology), by way of any product process or service that incorporates, utilizes or is made with the use of the
BCM technology. In consideration we agreed to pay BCM the following amounts:
|
·
|
a one time, non-refundable license fee of $25,000 which was paid in 2007;
|
|
·
|
an annual non-refundable maintenance fee of $20,000;
|
|
·
|
a one-time milestone payment of $75,000 upon FDA clearance or equivalent of clearance for therapeutic use (as of June 30, 2012,
we have not achieved FDA clearance); and
|
|
·
|
an installment of $25,000 upon our executing any sublicenses in respect of the BCM technology.
|
All payments to BCM are recorded as research and development
expenses. The license agreement will expire (unless terminated earlier for default or by us at our discretion) on the first day
following the tenth anniversary of our first commercial sale of licensed products. After termination, we will have a perpetual,
royalty free license to the BCM technology.
Under agreements with the OCS in Israel
regarding research and development projects, our Israeli subsidiary is committed to pay royalties to the OCS at rates between 3.5%
and 5% of the income resulting from this research and development, at an amount not to exceed the amount of the grants received
by our subsidiary as participation in the research and development program, plus interest at LIBOR. The obligation to pay these
royalties is contingent on actual income and in the absence of such income no payment is required. As of June 30, 2012, the aggregate
contingent liability amounted to approximately $6.8 million.
Pursuant to an agreement we entered into
on February 11, 2011 (effective as of January 31, 2011), the Regents of the University of Michigan (Michigan) have granted a worldwide
license for patent rights relating to certain uses of variants of clotting Factor VIII. The license agreement covers a portfolio
of two issued and three pending patents. In consideration we agreed to pay Michigan the following amounts:
|
·
|
an initial license fee of $25,000 which was paid in 2011;
|
|
·
|
an annual license fee in arrears of $10,000 rising to $50,000 following the grant by us of a sublicense or (if sooner) from
the sixth anniversary of the license agreement;
|
|
·
|
staged milestone payments of $750,000 (in aggregate), of which $400,000 will be recoupable against royalties;
|
|
·
|
royalties at an initial rate of 5% of net sales, reducing by a percentage point at predetermined thresholds to 2% upon cumulative
net sales exceeding $50 million;
|
|
·
|
sublicense fees at an initial rate of 6% of sublicensing revenues, reducing by a percentage point at predetermined thresholds
to 4% upon cumulative sublicensing revenues exceeding $50 million; and
|
|
·
|
patent maintenance costs.
|
The exclusive worldwide license from Michigan
is expected to expire in 2026 upon the expiration of the last to expire of the patent rights licensed. As of June 30, 2012, we
have paid the initial license fee and patent maintenance costs. No royalties or sublicense fees have yet accrued. Additionally,
we cannot estimate when we will begin selling any products that would require us to make any such royalty payments. Whether we
will be obligated to make royalty payments in the future is subject to the success of our product development efforts and, accordingly,
is inherently uncertain.
ITEM 3 — Quantitative and Qualitative Disclosures
about Market Risk
Not required.
ITEM 4 — Controls and Procedures
Evaluation of disclosure controls and procedures
As required by Exchange Act Rule 13a-15(b),
in connection with the filing of this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with
the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer
and principal financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2012, the end
of the period covered by this report.
Changes in Internal Control Over Financial
Reporting
There were no changes in our internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the quarter ended June 30, 2012 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II — OTHER INFORMATION
ITEM 1 — Legal Proceedings
We are not currently a party, as plaintiff
or defendant, to any legal proceedings which, individually or in the aggregate, are expected by us to have a material effect on
our business, financial condition or results of operation if determined adversely to us.
ITEM 1A — Risk Factors
There are no material changes from the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2011.
ITEM 2 — Unregistered Sale of Equity Securities
and Use of Proceeds
Recent Sales of Unregistered Securities
In the three months ended June 30, 2012,
the following securities were sold by us without registration under the Securities Act in transactions which have not been previously
described in a Current Report on Form 8-K. The securities described below were deemed exempt from registration under the Securities
Act in reliance upon Section 4(2) of the Securities Act and Regulation D thereunder. There were no underwriters employed in connection
with any of these transactions.
Common Stock Issued Directly
In June 2012, we issued 15,000 shares of
common stock to a consultant in compensation for investor relation services.
Common Stock Issued Upon Exercise of
Outstanding Warrants and Options
In May 2012, two consultants exercised
warrants to purchase 4,937 shares of common stock at an exercise price of $5.37 per share using the cashless exercise method. Using
this cashless exercise method, the consultants were issued 505 shares.
In May and June 2012, three investors exercised
warrants to purchase 46,711 shares of common stock at an exercise price of $5.37 per share using the cashless exercise method.
Using this cashless exercise method, the investors were issued 4,168 shares.
In June 2012, a director of our company
exercised options to purchase 4,286 shares of common stock at an exercise price of $6.55 per share, or an aggregate exercise price
of approximately $28 thousand.
In June 2012, an employee exercised options
to purchase 6,723 shares of common stock at an exercise price of $5.47 per share using the cashless exercise method. The employee
was issued 2,433 shares as a result of the option exercise.
In June 2012, a consultant exercised warrants
to purchase 1,188 shares of common stock at an exercise price of $5.32 per share and 143 shares of common stock at an exercise
price of $5.19 per share, each using the cashless exercise method. Using this cashless exercise method, the consultant was issued
363 shares. In addition, a consultant exercised warrants to purchase 4,675 shares of common stock at an exercise price of $4.99
per share using the cashless exercise method. Using this cashless exercise method, the consultant was issued 2,037 shares.
Options and Warrants Issued
In April 2012, we granted options to employees
to purchase an aggregate of 47,254 shares of common stock exercisable at a price of $5.13 per share. The options have a 10 year
term and vest in four equal annual tranches. The options were granted under our stock incentive plan.
In April 2012, we granted options to a
consultant to purchase 15,280 shares of common stock exercisable at a price of $5.13 per share. The options have a 10 year term
and vest in three equal annual tranches. The options were granted under our stock incentive plan.
In June 2012, we granted options to our
newly appointed Chairman of the Board to purchase 900,000 shares of common stock exercisable at a price of $10.80 per share. The
options have a 5 year term. Options to purchase 300,000 shares vested on July 19, 2012 and half of the remaining 600,000 options
will vest on each of June 30, 2013 and June 30, 2014. These options were granted outside of our stock incentive plan.
In June 2012, we granted options to each
of two consultants to purchase 25,000 shares of common stock at an exercise price of $6.86 per share. The options have a 10 year
term and vest in three equal annual tranches. The options were granted under our stock incentive plan.
Use of Proceeds from Registered Securities
On April 7, 2011, a registration statement
on Form S-1 (File No. 333-170425) relating to our initial public offering in the United States was declared effective by the SEC. In
this offering, we sold a total of 2,624,100 shares of common stock and 2,829,000 warrants for net proceeds of approximately $10.39
million. From the effective date of the registration statement through June 30, 2012, all of the net proceeds from this offering
have been used for research and development, clinical trials, working capital and general corporate purposes, including the payment
of regular compensation to our directors and officers. There was no material change in the use of proceeds from this offering from
that described in the final prospectus dated April 7, 2011 filed by us with the SEC pursuant to Rule 424(b).
Purchases of Equity Securities by the Issuer
and Affiliated Purchasers
None.
ITEM 3 — Defaults Upon Senior Securities
None.
ITEM 4 — Mine Safety Disclosures
Not applicable.
ITEM 5 — Other Information
None.
ITEM 6 — Exhibits
Exhibit No.
|
|
Description
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed November 5, 2010 (File No. 333-170425) and incorporated herein by reference).
|
|
|
|
3.2
|
|
Certificate of Amendment to Amended and Restated Certificate of Incorporation dated as of June 4, 2009 (previously filed as Exhibit 3.2 to the Company’s Registration Statement on Form S-1 filed November 5, 2010 (File No. 333-170425) and incorporated herein by reference).
|
|
|
|
3.3
|
|
Certificate of Amendment to Amended and Restated Certificate of Incorporation dated as of February 14, 2011 (previously filed as Exhibit 4.3 to the Company’s Post-Effective Amendment No. 1 to Form S-1 on Form S-3 filed July 16, 2012 (File No. 333-170425) and incorporated herein by reference).
|
|
|
|
3.4
|
|
Second Amended and Restated By-Laws (previously filed as Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.1
|
|
Form of Subscription Agreement, dated as of June 18, 2012, between Medgenics, Inc. and the Subscriber named therein (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 19, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.2
|
|
Form of Warrant Certificate, dated as of June 18, 2012 (previously filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 19, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.3
|
|
Warrant Agreement, dated as of June 18, 2012, between Medgenics, Inc. and Corporate Stock Transfer, Inc., as warrant agent (previously filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 19, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.4
|
|
Common Stock Purchase Warrant, dated as of June 18, 2012, issued to Maxim Partners LLC (previously filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed June 19, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.5
|
|
Registration Rights Agreement, dated as of June 18, 2012, by and among Medgenics, Inc. and the investors party thereto (previously filed as Exhibit 10.5 to the Company’s Current Report on Form 8-K filed June 19, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
10.6
|
|
First Amendment to Consulting Services Agreement, dated as of April 1, 2012, between Medgenics, Inc. and Eugene A. Bauer (filed herewith).
|
|
|
|
10.7
|
|
Medgenics, Inc. Non-Qualified Stock Option Award Terms between Medgenics, Inc. and Sol J. Barer (previously filed as Exhibit 4.7 to the Company’s Registration Statement on Form S-8 filed August 1, 2012 (File No. 333-182992) and incorporated herein by reference).
|
|
|
|
10.8
|
|
Director Appointment Letter, dated as of August 6, 2012, between Medgenics, Inc. and Sol J. Barer (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K/A filed August 8, 2012 (File No. 001-35112) and incorporated herein by reference).
|
|
|
|
31.1
|
|
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
|
|
|
|
31.2
|
|
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
|
|
|
|
32.1
|
|
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
|
|
|
|
101
|
|
Interactive Data File.*
|
* To be filed within 30 days in accordance with Rule 405(a)(2)
of Regulation S-T.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
MEDGENICS, INC.
|
|
|
|
Date: August 13, 2012
|
By:
|
/s/ Andrew L. Pearlman
|
|
|
Andrew L. Pearlman
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
Date: August 13, 2012
|
By:
|
/s/ Phyllis K. Bellin
|
|
|
Phyllis K. Bellin
|
|
|
Vice President – Administration
|
|
|
(Principal Accounting and Financial Officer)
|
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jul 2023 to Jul 2024